EDITORIALS

More Is Better: A Multimodality Approach to Cancer Cachexia

Egidio Del Fabbro
The Oncologist 2010; 15: 119-121; doi:10.1634/theoncologist.2010-0019
[Full Text] [PDF]  

SUMMARY: The author comments on the findings of Mantovani et al. with combination therapy to treat cancer cachexia published in this issue of The Oncologist.

Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?

Christos Vaklavas, Daniel Lenihan, Razelle Kurzrock, Apostolia Maria Tsimberidou
The Oncologist 2010; 15: 130-141; doi:10.1634/theoncologist.2009-0252
[Abstract] [Full Text] [PDF]  

SUMMARY: This review focuses on the potential cardiovascular toxicities associated with the use of bevacizumab, sunitinib, and sorafenib in order to increase awareness about these complications and to discuss their clinical significance and therapeutic interventions.

Sorafenib Therapy for Hepatocellular Carcinoma in an HIV–HCV Coinfected Patient: A Case Report

Giorgio Perboni, Paolo Costa, Giovanni Carlo Fibbia, Barbara Morandini, Alfredo Scalzini, Alberto Tagliani, Rita Cengarle, Enrico Aitini
The Oncologist 2010; 15: 142-145; doi:10.1634/theoncologist.2010-0010
[Abstract] [Full Text] [PDF]  

SUMMARY: The paper reports on the coadministration of highly effective antiretroviral therapy and sorafenib for hepatocellular carcinoma in a patient coinfected with HIV and hepatitis C virus. The simultaneous administration of these therapies was well tolerated and effective.

Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer

Christine J. O'Neill, Jennifer Oucharek, Diana Learoyd, Stan B. Sidhu
The Oncologist 2010; 15: 146-156; doi:10.1634/theoncologist.2009-0190
[Abstract] [Full Text] [PDF]  

SUMMARY: This review discusses both traditional and novel treatments for metastatic differentiated thyroid cancer with a particular focus on emerging treatments for patients with radioactive iodine–refractory disease.

Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions

Veena Shankaran, Jennifer Obel, Al B. Benson, III
The Oncologist 2010; 15: 157-167; doi:10.1634/theoncologist.2009-0221
[Abstract] [Full Text] [PDF]  

SUMMARY: This article reviews recent clinical trials supporting the predictive role of KRAS, recent changes to clinical guidelines and pharmaceutical labeling, investigational predictive molecular markers, and newer clinical trials targeting patients with mutated KRAS.

Current Management of Gallbladder Carcinoma

Andrew X. Zhu, Theodore S. Hong, Aram F. Hezel, David A. Kooby
The Oncologist 2010; 15: 168-181; doi:10.1634/theoncologist.2009-0302
[Abstract] [Full Text] [PDF]  

SUMMARY: This review discusses the current status and key issues involved in the management of gallbladder cancer.

Why Doesn't Imatinib Cure Chronic Myeloid Leukemia?

Robert L. Redner
The Oncologist 2010; 15: 182-186; doi:10.1634/theoncologist.2009-0297
[Abstract] [Full Text] [PDF]  

SUMMARY: This review explores the potential basis for the failure of imatinib to cure chronic myeloid leukemia.

Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms

Thomas E. Stinchcombe, Elizabeth M. Gore
The Oncologist 2010; 15: 187-195; doi:10.1634/theoncologist.2009-0298
[Abstract] [Full Text] [PDF]  

SUMMARY: The article reviews the currently available treatment options for patients with limited-stage small cell lung cancer.

IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?

Marianne Labussiere, Marc Sanson, Ahmed Idbaih, Jean-Yves Delattre
The Oncologist 2010; 15: 196-199; doi:10.1634/theoncologist.2009-0218
[Full Text] [PDF]  

SUMMARY: The manuscript examines the role of isocitrate dehydrogenase 1 and the IDH1 gene in the prognosis and therapy of glial tumors.

Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia

Giovanni Mantovani, Antonio Macciò, Clelia Madeddu, Roberto Serpe, Elena Massa, Mariele Dessì, Filomena Panzone, Paolo Contu
The Oncologist 2010; 15: 200-211; doi:10.1634/theoncologist.2009-0153
[Abstract] [Full Text] [PDF]  

SUMMARY: The authors report the results of a phase III clinical trial comparing five different treatment regimens in patients with cancer cachexia. Combination treatment with medroxyprogesterone or megestrol acetate, oral supplementation with eicosapentaenoic acid, L-carnitine, and thalidomide was most effective in these patients.

Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU

Alain Ravaud, Christelle de la Fouchardière, Julien Asselineau, Jean-Pierre Delord, Christine Do Cao, Patricia Niccoli, Patrice Rodien, Marc Klein, Bogdan Catargi
The Oncologist 2010; 15: 212-213; doi:10.1634/theoncologist.2009-0303
[Full Text] [PDF]  

SUMMARY: The article reports on the efficacy of sunitinib for thyroid carcinoma from a phase II trial.

In Reply

Maria João Bugalho
The Oncologist 2010; 15: 214; doi:10.1634/theoncologist.2009-0327
[Full Text] [PDF]  

SUMMARY: The author responds to comments on the study published by Ravaud et al. in The Oncologist on sunitinib for medullary thyroid carcinoma.

Fixed-Dose-Rate Gemcitabine: A Viable First-Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer

Michele Milella, Alain J. Gelibter, Maria Simona Pino, Giandominik Bossone, Paolo Marolla, Isabella Sperduti, Francesco Cognetti
The Oncologist 2010; 15: e1-e4; doi:10.1634/theoncologist.2008-0135
[Abstract] [Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.